secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001326110-24-000109
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio Q3 product revenue $6.0M, net loss narrows; ANKTIVA J-code set for Jan 2025
--------------------------------------------------------------------------------

- Net product revenue of $6.0M from ANKTIVA launch in Q3, up from $1.0M in Q2; diluted EPS -$0.14 vs -$0.19 YoY.
- Permanent J-code for ANKTIVA issued, effective Jan 1, 2025; medical coverage for over 200M lives secured.
- MAA submitted to UK MHRA for ANKTIVA; EU submission planned in Q4 2024, covering 30 countries.
- Cash and marketable securities $130.4M as of Sept 30; net loss attributable to stockholders -$85.7M vs -$95.6M YoY.
- ANKTIVA shelf life extended to 3 years; over 125,000 doses available for market and trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611024000109/0001326110-24-000109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611024000109/ibrx-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001326110-24-000109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer